These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

942 related items for PubMed ID: 31199090

  • 1. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J, HOPE Trial Investigators.
    N Engl J Med; 2019 Aug 08; 381(6):509-519. PubMed ID: 31199090
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J, Saraf SL, Gordeuk VR.
    Pharmacotherapy; 2020 Jun 08; 40(6):525-534. PubMed ID: 32343424
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
    Hutchaleelaha A, Patel M, Washington C, Siu V, Allen E, Oksenberg D, Gretler DD, Mant T, Lehrer-Graiwer J.
    Br J Clin Pharmacol; 2019 Jun 08; 85(6):1290-1302. PubMed ID: 30743314
    [Abstract] [Full Text] [Related]

  • 5. Voxelotor: A Novel Treatment for Sickle Cell Disease.
    Herity LB, Vaughan DM, Rodriguez LR, Lowe DK.
    Ann Pharmacother; 2021 Feb 08; 55(2):240-245. PubMed ID: 32674605
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
    Green ML, Savic RM, Tonda M, Jorga K, Washington CB.
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun 08; 11(6):698-710. PubMed ID: 35447017
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
    Rutherford-Parker NJ, Campbell ST, Colby JM, Shajani-Yi Z.
    Am J Clin Pathol; 2020 Oct 13; 154(5):627-634. PubMed ID: 32561909
    [Abstract] [Full Text] [Related]

  • 13. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 13; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials.
    Tanriverdi LH, Sarici A, Erkurt MA, Parlakpinar H.
    Int J Clin Pract; 2021 Jun 13; 75(6):e13967. PubMed ID: 33369007
    [Abstract] [Full Text] [Related]

  • 16. Voxelotor use in adults with sickle cell disease in a real-world setting.
    Curtis SA, Betancourt J, Kottapalli N, Campbell S, Minniti C.
    Am J Hematol; 2022 Mar 01; 97(3):E125-E128. PubMed ID: 34967959
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.